What Exome Asset Management LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 2011932 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 27.2K |
| −40.2% |
| $9.1M |
| 5.6% |
TGTXTG Therapeutics, Inc. | 164.9K | New | $9.1M | 5.6% |
COGTCogent Biosciences, Inc. | 210.5K | −24.4% | $8.1M | 5% |
IONSIonis Pharmaceuticals Inc | 88.2K | −19.9% | $7M | 4.3% |
LLYELI LILLY & Co | 5.5K | −21.7% | $6.6M | 4.1% |
ABVXAbivax S.A. | 46.9K | New | $6.2M | 3.9% |
ALMSAlumis Inc. | 204.4K | −26.8% | $5.8M | 3.5% |
CYTKCytokinetics Inc | 60.1K | −42.1% | $5.1M | 3.2% |
ELVNEnliven Therapeutics, Inc. | 100.2K | −54.5% | $5.1M | 3.1% |
VERAVera Therapeutics, Inc. | 97.3K | −15.4% | $4.2M | 2.6% |
UNHUnitedHealth Group Inc | 9.6K | −25.3% | $4M | 2.5% |
TXG10x Genomics, Inc. | 102.6K | −33.4% | $3.9M | 2.4% |
NTRANatera, Inc. | 13.8K | −26.0% | $3.7M | 2.3% |
QUREuniQure N.V. | 81.1K | New | $3.7M | 2.3% |
RYTMRhythm Pharmaceuticals, Inc. | 32.2K | −20.6% | $3.6M | 2.2% |
MAZEMaze Therapeutics, Inc. | 114.7K | +29.6% | $3.4M | 2.1% |
GLUEMonte Rosa Therapeutics, Inc. | 137.1K | −23.6% | $3.3M | 2% |
MLTXMoonLake Immunotherapeutics | 166.5K | −22.7% | $3.2M | 2% |
ALKSAlkermes plc. | 61.3K | −27.1% | $3.2M | 2% |
LQDALiquidia Corp | 39.2K | −14.4% | $3.1M | 1.9% |
UTHRUNITED THERAPEUTICS Corp | 5.4K | −23.3% | $2.9M | 1.8% |
GKOSGLAUKOS Corp | 19.9K | −4.8% | $2.8M | 1.7% |
ARWRArrowhead Pharmaceuticals, Inc. | 32.2K | −29.5% | $2.6M | 1.6% |
AGIOAgios Pharmaceuticals, Inc. | 70.5K | −43.6% | $2.6M | 1.6% |
CBIOCrescent Biopharma, Inc. | 127.8K | −16.6% | $2.3M | 1.4% |
AZNAstraZeneca PLC | 12K | New | $2.3M | 1.4% |
BSXBoston Scientific Corp | 48.3K | ±0% | $2.1M | 1.3% |
ADAGAdagene Inc. | 488.3K | −33.7% | $2.1M | 1.3% |
PENPenumbra Inc | 6.3K | ±0% | $2M | 1.2% |
ISRGIntuitive Surgical Inc | 4.9K | −22.8% | $2M | 1.2% |
VKTXViking Therapeutics, Inc. | 47.9K | New | $1.9M | 1.2% |
OCULOcular Therapeutix, Inc | 181.6K | New | $1.8M | 1.1% |
EQEquillium, Inc. | 553K | New | $1.8M | 1.1% |
ASNDAscendis Pharma A/S | 6.6K | New | $1.8M | 1.1% |
CRBPCorbus Pharmaceuticals Holdings, Inc. | 184.9K | −21.0% | $1.7M | 1.1% |
CTMXCytomX Therapeutics, Inc. | 460.1K | −11.8% | $1.7M | 1.1% |
VSTMVerastem, Inc. | 429K | −32.6% | $1.6M | 1% |
NKTRNektar Therapeutics | 22.4K | New | $1.6M | 1% |
CLPTClearPoint Neuro, Inc. | 83.6K | New | $1.5M | 0.9% |
INSMINSMED Inc | 13.9K | −47.9% | $1.5M | 0.9% |
CAICaris Life Sciences, Inc. | 78.2K | New | $1.4M | 0.9% |
BBIOBridgeBio Pharma, Inc. | 18.4K | −72.8% | $1.4M | 0.8% |
ZBIOZenas BioPharma, Inc. | 52.4K | −35.0% | $1.3M | 0.8% |
NBPNovaBridge Biosciences | 577K | ±0% | $1.1M | 0.7% |
ESTAEstablishment Labs Holdings Inc. | 13.1K | ±0% | $1.1M | 0.7% |
RLAYRelay Therapeutics, Inc. | 47.5K | −82.9% | $889.3K | 0.5% |
GERNGeron Corp | 624K | New | $798.8K | 0.5% |
DRUGBright Minds Biosciences Inc. | 10.1K | New | $709.7K | 0.4% |
CMPXCompass Therapeutics, Inc. | 276.2K | New | $604.8K | 0.4% |
REPLReplimune Group, Inc. | 40.4K | New | $446.8K | 0.3% |
ABUSArbutus Biopharma Corp | 50.2K | −33.5% | $240.8K | 0.1% |
